GSK PLC Sponsored ADR $GSK Shares Sold by Callodine Capital Management LP

Key Points

• Callodine Capital Management LP has reduced its stake in GSK PLC by 18.6%, selling 130,000 shares and now holding 570,000 shares, which is 3.7% of its portfolio.
• GSK reported a quarterly earnings per share (EPS) of $1.23, exceeding analysts' expectations of $1.12, with a revenue of $10.64 billion, compared to the expected $7.92 billion.
• The company has declared a quarterly dividend of $0.4206 per share, leading to an annualized yield of 4.2%, with a payout ratio of 77.78%.

Callodine Capital Management LP lessened its stake in shares of GSK PLC Sponsored ADR (NYSE:GSK - Free Report) by 18.6% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 570,000 shares of the pharmaceutical company's stock after selling 130,000 shares during the quarter. GSK accounts for 3.7% of Callodine Capital Management LP's investment portfolio, making the stock its 11th biggest position. Callodine Capital Management LP's holdings in GSK were worth $22,082,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also modified their holdings of the company. HHM Wealth Advisors LLC lifted its stake in shares of GSK by 222.2% in the first quarter. HHM Wealth Advisors LLC now owns 667 shares of the pharmaceutical company's stock worth $26,000 after acquiring an additional 460 shares in the last quarter. Costello Asset Management INC acquired a new position in shares of GSK in the first quarter worth about $31,000. Richardson Financial Services Inc. lifted its stake in shares of GSK by 127.9% in the first quarter. Richardson Financial Services Inc. now owns 841 shares of the pharmaceutical company's stock worth $33,000 after acquiring an additional 472 shares in the last quarter. Olde Wealth Management LLC acquired a new position in shares of GSK in the first quarter worth about $36,000. Finally, Cary Street Partners Investment Advisory LLC lifted its stake in shares of GSK by 525.9% in the first quarter. Cary Street Partners Investment Advisory LLC now owns 1,014 shares of the pharmaceutical company's stock worth $39,000 after acquiring an additional 852 shares in the last quarter. Institutional investors and hedge funds own 15.74% of the company's stock.

Analyst Upgrades and Downgrades

GSK has been the topic of several recent analyst reports. Wall Street Zen upgraded GSK from a "hold" rating to a "buy" rating in a research note on Sunday, August 3rd. Berenberg Bank reissued a "hold" rating on shares of GSK in a report on Tuesday, June 3rd. Six analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Reduce" and a consensus price target of $37.38.

GSK Stock Up 0.6%

GSK stock traded up $0.24 during midday trading on Monday, hitting $39.68. The stock had a trading volume of 3,590,956 shares, compared to its average volume of 3,177,226. The company has a current ratio of 0.87, a quick ratio of 0.57 and a debt-to-equity ratio of 1.07. The stock has a market cap of $80.82 billion, a P/E ratio of 18.37, a P/E/G ratio of 1.72 and a beta of 0.53. GSK PLC Sponsored ADR has a 12 month low of $31.72 and a 12 month high of $44.26. The business has a fifty day moving average price of $38.40 and a 200 day moving average price of $38.25.

GSK (NYSE:GSK - Get Free Report) last posted its earnings results on Wednesday, July 30th. The pharmaceutical company reported $1.23 EPS for the quarter, beating the consensus estimate of $1.12 by $0.11. The company had revenue of $10.64 billion during the quarter, compared to analyst estimates of $7.92 billion. GSK had a return on equity of 49.22% and a net margin of 10.81%.The business's revenue was up 1.3% compared to the same quarter last year. During the same period in the prior year, the company earned $0.43 earnings per share. GSK has set its FY 2025 guidance at 4.590-4.590 EPS. Research analysts predict that GSK PLC Sponsored ADR will post 4.14 EPS for the current year.

GSK Cuts Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, October 9th. Stockholders of record on Friday, August 15th will be issued a dividend of $0.4206 per share. The ex-dividend date of this dividend is Friday, August 15th. This represents a $1.68 annualized dividend and a dividend yield of 4.2%. GSK's dividend payout ratio is 77.78%.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.